NEW YORK (GenomeWeb News) – Tepnel Life Sciences said today that its DNA-based test for the early detection of familial hypercholesterolemia has received the CE Mark and has been commercially launched in Europe.
Manchester, England-based Tepnel said that the Elucigene FH20 kit can rapidly determine the 20 genetic mutations responsible for the disease that are most commonly found in a UK-based population.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.